Acumen Pharmaceuticals (ABOS) Interest Expenses (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Interest Expenses of $1.1 million for Q1 2026, up 46.04% sequentially from $732000.0 in Q4 2025, and up 4.5% YoY from $1.0 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Interest Expenses (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Interest Expenses for 7 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Interest Expenses rose 4.5% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 19.68% YoY) and the FY2025 annual result came in at $85.5 million, up 51.53% from the prior year.
- Interest Expenses rose to $1.1 million in Q1 2026 per ABOS's latest filing, from $732000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $39.8 million in Q3 2022 and troughed at -$114000.0 in Q4 2022.
- A 5-year average of $3.9 million and a median of $1.0 million in 2024 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 173021.74% in 2022, down 395.65% in 2022.
- Over 5 years, Interest Expenses stood at -$114000.0 in 2022, then surged by 248.25% to $169000.0 in 2023, then soared by 976.92% to $1.8 million in 2024, then sank by 59.78% to $732000.0 in 2025, then soared by 46.04% to $1.1 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $1.1 million, $732000.0, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | 1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.09 Mn |
| Jun 30, 2026 | 1.09 Mn |
| Mar 31, 2026 | 1.07 Mn |
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 732,000.00 |
| Dec 31, 2025 | 732,000.00 |
| Sep 30, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 1.02 Mn |
| Mar 31, 2025 | 1.02 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |